Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

NCT00566735 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00566735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00566735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
January 31, 2008
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, major depression, schizoaffective disorder